- Home
- FENC vs LYEL Comparison
FENC vs LYEL Comparison
Compare FENC & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- LYEL
- Stock Information
- Founded
- FENC 1996
- LYEL 2018
- Country
- FENC United States
- LYEL United States
- Employees
- FENC N/A
- LYEL N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- LYEL Health Care
- Exchange
- FENC Nasdaq
- LYEL Nasdaq
- Market Cap
- FENC 225.4M
- LYEL 207.7M
- IPO Year
- FENC 2001
- LYEL 2021
- Fundamental
- Price
- FENC $8.36
- LYEL $10.58
- Analyst Decision
- FENC Strong Buy
- LYEL Sell
- Analyst Count
- FENC 2
- LYEL 2
- Target Price
- FENC $13.50
- LYEL $15.00
- AVG Volume (30 Days)
- FENC 56.4K
- LYEL 71.4K
- Earning Date
- FENC 08-14-2025
- LYEL 08-12-2025
- Dividend Yield
- FENC N/A
- LYEL N/A
- EPS Growth
- FENC N/A
- LYEL N/A
- EPS
- FENC N/A
- LYEL N/A
- Revenue
- FENC $33,302,000.00
- LYEL $60,000.00
- Revenue This Year
- FENC $0.85
- LYEL N/A
- Revenue Next Year
- FENC $55.16
- LYEL N/A
- P/E Ratio
- FENC N/A
- LYEL N/A
- Revenue Growth
- FENC N/A
- LYEL 11.11
- 52 Week Low
- FENC $3.96
- LYEL $7.65
- 52 Week High
- FENC $9.42
- LYEL $32.40
- Technical
- Relative Strength Index (RSI)
- FENC 48.45
- LYEL 48.25
- Support Level
- FENC $7.17
- LYEL $9.28
- Resistance Level
- FENC $9.42
- LYEL $10.83
- Average True Range (ATR)
- FENC 0.54
- LYEL 0.89
- MACD
- FENC 0.02
- LYEL -0.17
- Stochastic Oscillator
- FENC 52.89
- LYEL 27.48
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.